

Hans Lilja

List of Publications by Citations

Source: <https://exaly.com/author-pdf/417171/hans-lilja-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

350
papers

26,079
citations

78
h-index

152
g-index

374
ext. papers

29,247
ext. citations

6.4
avg, IF

6.53
L-index

#	Paper	IF	Citations
350	Screening and prostate-cancer mortality in a randomized European study. <i>New England Journal of Medicine</i> , 2009 , 360, 1320-8	59.2	2828
349	Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. <i>Lancet, The</i> , 2014 , 384, 2027-35	40	910
348	Prostate-cancer mortality at 11 years of follow-up. <i>New England Journal of Medicine</i> , 2012 , 366, 981-90	59.2	875
347	Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. <i>Lancet Oncology, The</i> , 2010 , 11, 725-32	21.7	663
346	Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. <i>Nature Reviews Cancer</i> , 2008 , 8, 268-78	31.3	605
345	Differential exoprotease activities confer tumor-specific serum peptidome patterns. <i>Journal of Clinical Investigation</i> , 2006 , 116, 271-84	15.9	593
344	Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. <i>Journal of Urology</i> , 1993 , 150, 100-5	2.5	552
343	Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 7053-8	12.9	546
342	A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. <i>Journal of Clinical Investigation</i> , 1985 , 76, 1899-903	15.9	532
341	Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. <i>FEBS Journal</i> , 1990 , 194, 755-63		486
340	National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. <i>Clinical Chemistry</i> , 2008 , 54, e11-79 ⁵	5.5	451
339	Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3973-8	2.2	372
338	Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. <i>Clinical Cancer Research</i> , 2007 , 13, 2023-9	12.9	290
337	Molecular cloning of human prostate specific antigen cDNA. <i>FEBS Letters</i> , 1987 , 214, 317-22	3.8	288
336	Prevention and early detection of prostate cancer. <i>Lancet Oncology, The</i> , 2014 , 15, e484-92	21.7	277
335	Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. <i>Journal of Clinical Investigation</i> , 1987 , 80, 281-5	15.9	269
334	Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios. <i>Journal of Urology</i> , 1995 , 154, 1090-5	2.5	268

333	Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. <i>Urology</i> , 1995 , 45, 729-44	1.6	259
332	The role of SPINK1 in ETS rearrangement-negative prostate cancers. <i>Cancer Cell</i> , 2008 , 13, 519-28	24.3	254
331	Microfluidic, label-free enrichment of prostate cancer cells in blood based on acoustophoresis. <i>Analytical Chemistry</i> , 2012 , 84, 7954-62	7.8	238
330	Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. <i>Journal of the National Cancer Institute</i> , 2003 , 95, 990-1000	9.7	234
329	A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden. <i>BMC Medicine</i> , 2008 , 6, 19	11.4	183
328	Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 398-403	2.2	180
327	Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. <i>Biochemical and Biophysical Research Communications</i> , 1997 , 238, 549-55	3.4	180
326	The human cationic antimicrobial protein (hCAP-18) is expressed in the epithelium of human epididymis, is present in seminal plasma at high concentrations, and is attached to spermatozoa. <i>Infection and Immunity</i> , 2000 , 68, 4297-302	3.7	179
325	Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2493-8	2.2	172
324	Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. <i>Clinical Cancer Research</i> , 2009 , 15, 2091-7	12.9	170
323	A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acidic protein. <i>Biochemical Journal</i> , 2002 , 368, 233-42	3.8	168
322	Three predominant proteins secreted by the human prostate gland. <i>Prostate</i> , 1988 , 12, 29-38	4.2	168
321	A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. <i>European Urology</i> , 2019 , 76, 43-51	10.2	163
320	Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. <i>Journal of the National Cancer Institute</i> , 2007 , 99, 1484-9	9.7	160
319	Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study. <i>European Urology</i> , 2014 , 66, 489-99	10.2	156
318	TMPRSS2-ERG status in circulating tumor cells as a predictive biomarker of sensitivity in castration-resistant prostate cancer patients treated with abiraterone acetate. <i>European Urology</i> , 2011 , 60, 897-904	10.2	156
317	Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. <i>Journal of Clinical Oncology</i> , 2007 , 25, 431-6	2.2	156
316	Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study. <i>BMJ, The</i> , 2010 , 341, c4521	5.9	153

315	Acoustic whole blood plasmapheresis chip for prostate specific antigen microarray diagnostics. <i>Analytical Chemistry</i> , 2009 , 81, 6030-7	7.8	153
314	New Nomenclature for the Human Tissue Kallikrein Gene Family. <i>Clinical Chemistry</i> , 2000 , 46, 1855-1858	5.5	151
313	Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study. <i>BMJ, The</i> , 2013 , 346, f2023	5.9	150
312	Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). <i>European Urology</i> , 2009 , 56, 584-91	10.2	146
311	NF-kappaB regulates androgen receptor expression and prostate cancer growth. <i>American Journal of Pathology</i> , 2009 , 175, 489-99	5.8	145
310	Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. <i>FEBS Journal</i> , 1994 , 220, 45-53		139
309	Enzymatic action of prostate-specific antigen (PSA or hK3): substrate specificity and regulation by Zn(2+), a tight-binding inhibitor. <i>Prostate</i> , 2000 , 45, 132-9	4.2	137
308	Genomic Predictors of Outcome in Prostate Cancer. <i>European Urology</i> , 2015 , 68, 1033-44	10.2	136
307	Tumor markers in prostate cancer I: blood-based markers. <i>Acta Oncologica</i> , 2011 , 50 Suppl 1, 61-75	3.2	133
306	miR-34c is downregulated in prostate cancer and exerts tumor suppressive functions. <i>International Journal of Cancer</i> , 2010 , 127, 2768-76	7.5	131
305	Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. <i>Prostate</i> , 1988 , 12, 39-46	4.2	128
304	Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. <i>Urology</i> , 1994 , 43, 427-34	1.6	125
303	Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>European Urology</i> , 2015 , 68, 139-46	10.2	123
302	A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index. <i>European Urology</i> , 2012 , 62, 78-84	10.2	123
301	Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system. <i>Journal of Clinical Investigation</i> , 1992 , 89, 1094-101	15.9	123
300	Testosterone as a predictor of pathological stage in clinically localized prostate cancer. <i>Journal of Urology</i> , 2005 , 173, 1935-7	2.5	118
299	Predicting high-grade cancer at ten-core prostate biopsy using four kallikrein markers measured in blood in the ProtecT study. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	116
298	PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. <i>International Journal of Cancer</i> , 2007 , 120, 170-4	7.5	116

297	Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. <i>Urology</i> , 1996 , 48, 317-25	1.6	115
296	NCCN clinical practice guidelines in oncology: prostate cancer early detection. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010 , 8, 240-62	7.3	108
295	Acoustofluidic, label-free separation and simultaneous concentration of rare tumor cells from white blood cells. <i>Analytical Chemistry</i> , 2015 , 87, 9322-8	7.8	107
294	Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival. <i>Clinical Chemistry</i> , 2009 , 55, 765-73	5.5	106
293	In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin in blood samples. <i>Urology</i> , 1996 , 48, 81-7	1.6	106
292	A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. <i>Biological Chemistry</i> , 2006 , 387, 637-41	4.5	102
291	Prediction of significant prostate cancer diagnosed 20 to 30 years later with a single measure of prostate-specific antigen at or before age 50. <i>Cancer</i> , 2011 , 117, 1210-9	6.4	101
290	A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. <i>Clinical Cancer Research</i> , 2010 , 16, 3232-9	12.9	97
289	Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2581-4	2.2	97
288	Total levels of tissue inhibitor of metalloproteinases 1 in plasma yield high diagnostic sensitivity and specificity in patients with colon cancer. <i>Clinical Cancer Research</i> , 2002 , 8, 156-64	12.9	97
287	Liquefaction of coagulated human semen. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1984 , 44, 447-52	2	96
286	miR-205 negatively regulates the androgen receptor and is associated with adverse outcome of prostate cancer patients. <i>British Journal of Cancer</i> , 2013 , 108, 1668-76	8.7	95
285	Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. <i>Cancer</i> , 2004 , 100, 1397-405	6.4	95
284	Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study. <i>European Urology</i> , 2015 , 68, 207-13	10.2	92
283	Prostate specific antigen predominantly forms a complex with alpha 1-antichymotrypsin in blood. Implications for procedures to measure prostate specific antigen in serum. <i>Cancer</i> , 1992 , 70, 230-4	6.4	90
282	Microchannel acoustophoresis does not impact survival or function of microglia, leukocytes or tumor cells. <i>PLoS ONE</i> , 2013 , 8, e64233	3.7	88
281	A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands. <i>British Journal of Cancer</i> , 2010 , 103, 708-14	8.7	87
280	An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detection. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 462-9	9.7	87

279	A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. <i>Journal of Urology</i> , 1996 , 156, 350-354	2.5	85
278	Biology of prostate-specific antigen. <i>Urology</i> , 2003 , 62, 27-33	1.6	83
277	Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population. <i>Journal of Clinical Oncology</i> , 2008 , 26, 835-41	2.2	82
276	Importance of prostate volume in the European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators: results from the prostate biopsy collaborative group. <i>World Journal of Urology</i> , 2012 , 30, 149-55	4	81
275	Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium. <i>Urology</i> , 1993 , 42, 502-10	1.6	80
274	Prostate cancer screening decreases the absolute risk of being diagnosed with advanced prostate cancer--results from a prospective, population-based randomized controlled trial. <i>European Urology</i> , 2007 , 51, 659-64	10.2	79
273	Molecular cloning of epididymal and seminal vesicular transcripts encoding a semenogelin-related protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992 , 89, 4559-63	11.5	79
272	Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. <i>European Urology</i> , 2019 , 76, 831-842	10.2	78
271	The evolution of a genetic locus encoding small serine proteinase inhibitors. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 333, 383-9	3.4	77
270	Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. <i>BJU International</i> , 2011 , 107, 28-39	5.6	76
269	A single inlet two-stage acoustophoresis chip enabling tumor cell enrichment from white blood cells. <i>Lab on A Chip</i> , 2015 , 15, 2102-9	7.2	75
268	SIGNIFICANCE OF DIFFERENT MOLECULAR FORMS OF SERUM PSA: The Free, Noncomplexed Form of PSA Versus that Complexed to α -Antichymotrypsin. <i>Urologic Clinics of North America</i> , 1993 , 20, 681-686	2.9	75
267	The predominant protein in human seminal coagulate. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1985 , 45, 635-41	2	74
266	Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. <i>BMC Medicine</i> , 2008 , 6, 6	11.4	73
265	The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. <i>Clinical Cancer Research</i> , 2010 , 16, 4374-81	12.9	72
264	Association of cysteine-rich secretory protein 3 and beta-microseminoprotein with outcome after radical prostatectomy. <i>Clinical Cancer Research</i> , 2007 , 13, 4130-8	12.9	72
263	Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. <i>Journal of Urology</i> , 2000 , 163, 1491-7	2.5	72
262	Discrimination of Prostate Cancer from Benign Disease by Plasma Measurement of Intact, Free Prostate-specific Antigen Lacking an Internal Cleavage Site at Lys145-Lys146. <i>Clinical Chemistry</i> , 2001 , 47, 1415-1423	5.5	72

261	Enzymatic action of human glandular kallikrein 2 (hK2). Substrate specificity and regulation by Zn ²⁺ and extracellular protease inhibitors. <i>FEBS Journal</i> , 1999 , 262, 781-9		72
260	Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. <i>Prostate</i> , 2001 , 49, 101-9	4.2	71
259	A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011 , 20, 255-61	4	70
258	Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. <i>Archives of Internal Medicine</i> , 2005 , 165, 1857-61		70
257	DISCRIMINATION OF MEN WITH PROSTATE CANCER FROM THOSE WITH BENIGN DISEASE BY MEASUREMENTS OF HUMAN GLANDULAR KALLIKREIN 2 (HK2) IN SERUM. <i>Journal of Urology</i> , 2000 , 163, 311-316	2.5	69
256	The rs10993994 risk allele for prostate cancer results in clinically relevant changes in microseminoprotein-beta expression in tissue and urine. <i>PLoS ONE</i> , 2010 , 5, e13363	3.7	68
255	Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum. <i>Urology</i> , 1998 , 51, 57-62	1.6	67
254	A Four-kallikrein Panel Predicts High-grade Cancer on Biopsy: Independent Validation in a Community Cohort. <i>European Urology</i> , 2016 , 69, 505-11	10.2	65
253	Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial. <i>European Urology</i> , 2015 , 68, 354-60	10.2	64
252	Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam. <i>European Urology</i> , 2013 , 64, 693-9	10.2	64
251	Susceptibility loci associated with prostate cancer progression and mortality. <i>Clinical Cancer Research</i> , 2010 , 16, 2819-32	12.9	64
250	A panel of kallikrein markers can predict outcome of prostate biopsy following clinical work-up: an independent validation study from the European Randomized Study of Prostate Cancer screening, France. <i>BMC Cancer</i> , 2010 , 10, 635	4.8	64
249	Translational crossroads for biomarkers. <i>Clinical Cancer Research</i> , 2005 , 11, 6103-8	12.9	64
248	Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. <i>Urology</i> , 2000 , 55, 694-9	1.6	64
247	Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3591-7	2.2	63
246	Serum cystatin C is a more sensitive and more accurate marker of glomerular filtration rate than enzymatic measurements of creatinine in renal transplantation. <i>Nephron Physiology</i> , 2003 , 94, p19-27		62
245	Streptavidin-Polyvinylamine Conjugates Labeled with a Europium Chelate: Applications in Immunoassay, Immunohistochemistry, and Microarrays. <i>Clinical Chemistry</i> , 2000 , 46, 1450-1455	5.5	62
244	Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. <i>Urology</i> , 1996 , 48, 882-8	1.6	62

243	Imaging androgen receptor signaling with a radiotracer targeting free prostate-specific antigen. <i>Cancer Discovery</i> , 2012 , 2, 320-7	24.4	61
242	Lead time associated with screening for prostate cancer. <i>International Journal of Cancer</i> , 2004 , 108, 122-9.5	9.5	61
241	Molecular cloning of a small prostate protein, known as beta-microsemenoprotein, PSP94 or beta-inhibin, and demonstration of transcripts in non-genital tissues. <i>Biochemical and Biophysical Research Communications</i> , 1989 , 164, 1310-5	3.4	60
240	Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen. <i>BMC Medicine</i> , 2014 , 12, 26	11.4	58
239	Analytic and clinical validation of a prostate cancer-enhanced messenger RNA detection assay in whole blood as a prognostic biomarker for survival. <i>European Urology</i> , 2014 , 65, 1191-7	10.2	58
238	Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C. <i>Clinical Chemistry</i> , 2006 , 52, 235-9	5.5	57
237	Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab) ₂ fragments. <i>Analytical Chemistry</i> , 2006 , 78, 7809-15	7.8	57
236	beta-Microseminoprotein binds CRISP-3 in human seminal plasma. <i>Biochemical and Biophysical Research Communications</i> , 2005 , 333, 555-61	3.4	55
235	Prognostic value of serum markers for prostate cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005 , 64-81		55
234	Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study. <i>BMJ, The</i> , 2014 , 348, g2296	5.9	53
233	Impact of recent screening on predicting the outcome of prostate cancer biopsy in men with elevated prostate-specific antigen: data from the European Randomized Study of Prostate Cancer Screening in Gothenburg, Sweden. <i>Cancer</i> , 2010 , 116, 2612-20	6.4	53
232	The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. <i>Prostate</i> , 2003 , 54, 181-6	4.2	53
231	Production and Characterization of Novel Anti-Prostate-specific Antigen (PSA) Monoclonal Antibodies That Do Not Detect Internally Cleaved Lys145-Lys146 Inactive PSA. <i>Clinical Chemistry</i> , 2000 , 46, 1610-1618	5.5	53
230	Sensitive and Specific Immunodetection of Human Glandular Kallikrein 2 in Serum. <i>Clinical Chemistry</i> , 2000 , 46, 198-206	5.5	53
229	Acoustic Enrichment of Extracellular Vesicles from Biological Fluids. <i>Analytical Chemistry</i> , 2018 , 90, 8011-8019	11.8	53
228	Prostate-specific antigen velocity for early detection of prostate cancer: result from a large, representative, population-based cohort. <i>European Urology</i> , 2009 , 56, 753-60	10.2	51
227	Semenogelin I and semenogelin II, the major gel-forming proteins in human semen, are substrates for transglutaminase. <i>FEBS Journal</i> , 1998 , 252, 216-21		51
226	Determination and analysis of antigenic epitopes of prostate specific antigen (PSA) and human glandular kallikrein 2 (hK2) using synthetic peptides and computer modeling. <i>Protein Science</i> , 1998 , 7, 259-69	6.3	51

225	Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2012 , 30, 181-7	4	50
224	Blood biomarker levels to aid discovery of cancer-related single-nucleotide polymorphisms: kallikreins and prostate cancer. <i>Cancer Prevention Research</i> , 2010 , 3, 611-9	3.2	50
223	Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. <i>Clinical Chemistry</i> , 2007 , 53, 233-40	5.5	49
222	Expression of prostate-specific antigen (PSA) and human glandular kallikrein 2 (hK2) in ileum and other extraprostatic tissues. <i>International Journal of Cancer</i> , 2005 , 113, 290-7	7.5	49
221	Association of cancer with moderately impaired renal function at baseline in a large, representative, population-based cohort followed for up to 30 years. <i>International Journal of Cancer</i> , 2013 , 133, 1452-8	7.5	48
220	Taxon-specific evolution of glandular kallikrein genes and identification of a progenitor of prostate-specific antigen. <i>Genomics</i> , 2004 , 84, 147-56	4.3	48
219	Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. <i>Urology</i> , 1996 , 48, 240-8	1.6	47
218	Isolation and characterization of the major gel proteins in human semen, semenogelin I and semenogelin II. <i>FEBS Journal</i> , 1996 , 238, 48-53		47
217	miR-145 suppress the androgen receptor in prostate cancer cells and correlates to prostate cancer prognosis. <i>Carcinogenesis</i> , 2015 , 36, 858-66	4.6	46
216	Enhanced discrimination of benign from malignant prostatic disease by selective measurements of cleaved forms of urokinase receptor in serum. <i>Clinical Chemistry</i> , 2006 , 52, 838-44	5.5	46
215	Time-resolved fluorescence imaging for quantitative histochemistry using lanthanide chelates in nanoparticles and conjugated to monoclonal antibodies. <i>Luminescence</i> , 2000 , 15, 389-97	2.5	46
214	Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. <i>International Journal of Cancer</i> , 2006 , 118, 1234-40	7.5	44
213	Inhibition of dendropoiesis by tumor derived and purified prostate specific antigen. <i>Journal of Urology</i> , 2003 , 170, 2026-30	2.5	44
212	Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug. <i>Prostate</i> , 2006 , 66, 358-68	4.2	43
211	The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. <i>Urology</i> , 2016 , 91, 12-8	1.6	42
210	Serum markers for prostate cancer: a rational approach to the literature. <i>European Urology</i> , 2008 , 54, 31-40	10.2	42
209	Development of sensitive immunoassays for free and total human glandular kallikrein 2. <i>Clinical Chemistry</i> , 2004 , 50, 1607-17	5.5	42
208	Concurrent isolation of lymphocytes and granulocytes using prefocused free flow acoustophoresis. <i>Analytical Chemistry</i> , 2015 , 87, 5596-604	7.8	41

207	Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men. <i>European Urology</i> , 2012 , 61, 471-7	10.2	41
206	Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. <i>Prostate</i> , 2006 , 66, 591-603	4.2	41
205	Isolation and characterization of two minor fractions of alpha 1-antitrypsin by high-performance liquid chromatographic chromatofocusing. <i>Journal of Chromatography A</i> , 1985 , 327, 173-7	4.5	41
204	Genome-wide association study of prostate-specific antigen levels identifies novel loci independent of prostate cancer. <i>Nature Communications</i> , 2017 , 8, 14248	17.4	40
203	The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable. <i>Journal of Urology</i> , 2004 , 171, 1500-3	2.5	40
202	Molecular forms of serum prostate-specific antigen. The clinical value of percent free prostate-specific antigen. <i>Urologic Clinics of North America</i> , 1997 , 24, 353-65	2.9	39
201	Discrimination of Benign From Malignant Prostatic Disease by Selective Measurements of Single Chain, Intact Free Prostate Specific Antigen. <i>Journal of Urology</i> , 2002 , 168, 1917-1922	2.5	39
200	Diagnostic value of percent free prostate-specific antigen: retrospective analysis of a population-based screening study with emphasis on men with PSA levels less than 3.0 ng/mL. <i>Urology</i> , 1999 , 53, 945-50	1.6	38
199	Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. <i>International Journal of Cancer</i> , 2007 , 120, 1499-504	7.5	37
198	High-speed biomarker identification utilizing porous silicon nanovial arrays and MALDI-TOF mass spectrometry. <i>Electrophoresis</i> , 2006 , 27, 1093-103	3.6	37
197	Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment. <i>Nephrology Dialysis Transplantation</i> , 2003 , 18, 598-603	4.3	37
196	Integrated selective enrichment target--a microtechnology platform for matrix-assisted laser desorption/ionization-mass spectrometry applied on protein biomarkers in prostate diseases. <i>Electrophoresis</i> , 2004 , 25, 3769-77	3.6	37
195	Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy. <i>Journal of Urology</i> , 1999 , 162, 2029-34; discussion 2034-5	2.5	37
194	ENSAM: Europium Nanoparticles for Signal enhancement of Antibody Microarrays on nanoporous silicon. <i>Journal of Proteome Research</i> , 2008 , 7, 1308-14	5.6	36
193	The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. <i>International Journal of Cancer</i> , 2007 , 121, 2212-7	7.5	36
192	Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable. <i>Journal of Urology</i> , 2003 , 169, 1720-3	2.5	36
191	Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies. <i>Journal of Urology</i> , 2003 , 170, 2269-73	2.5	36
190	Quantitative Reverse Transcription-PCR Assay with an Internal Standard for the Detection of Prostate-specific Antigen mRNA. <i>Clinical Chemistry</i> , 1999 , 45, 1397-1407	5.5	35

189	Sensitive and specific enzymatic assay for the determination of precursor forms of prostate-specific antigen after an activation step. <i>Clinical Chemistry</i> , 2002 , 48, 1257-64	5.5	35
188	Levels of beta-microseminoprotein in blood and risk of prostate cancer in multiple populations. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 237-43	9.7	34
187	Identification of a novel proteoform of prostate specific antigen (SNP-L132I) in clinical samples by multiple reaction monitoring. <i>Molecular and Cellular Proteomics</i> , 2013 , 12, 2761-73	7.6	34
186	Prostate-specific kallikrein-related peptidases and their relation to prostate cancer biology and detection. Established relevance and emerging roles. <i>Thrombosis and Haemostasis</i> , 2013 , 110, 484-92	7	34
185	Comparability of the Tandem-R and IMx assays for the measurement of serum prostate-specific antigen. <i>Urology</i> , 1994 , 44, 512-8	1.6	34
184	Production and activation of recombinant hK2 with propeptide mutations resulting in high expression levels. <i>FEBS Journal</i> , 1999 , 266, 1050-5		33
183	Familial α -Antichymotrypsin Deficiency. <i>Acta Medica Scandinavica</i> , 2009 , 220, 447-453		32
182	Association of reported prostate cancer risk alleles with PSA levels among men without a diagnosis of prostate cancer. <i>Prostate</i> , 2009 , 69, 419-27	4.2	32
181	Prostate kallikrein markers in diagnosis, risk stratification and prognosis. <i>Nature Reviews Urology</i> , 2009 , 6, 384-91	5.5	32
180	Circulating biomarkers for prostate cancer. <i>World Journal of Urology</i> , 2007 , 25, 111-9	4	32
179	Clinical-Scale Cell-Surface-Marker Independent Acoustic Microfluidic Enrichment of Tumor Cells from Blood. <i>Analytical Chemistry</i> , 2017 , 89, 11954-11961	7.8	31
178	Screening for prostate cancer: early detection or overdetection?. <i>Annual Review of Medicine</i> , 2012 , 63, 161-70	17.4	31
177	Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. <i>Prostate</i> , 2005 , 63, 13-8	4.2	31
176	Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells. <i>Prostate Cancer and Prostatic Diseases</i> , 1999 , 2, 91-97	6.2	31
175	Screening for prostate cancer: an update. <i>Canadian Journal of Urology</i> , 2008 , 15, 4363-74	0.8	31
174	miR-183 in prostate cancer cells positively regulates synthesis and serum levels of prostate-specific antigen. <i>European Urology</i> , 2015 , 68, 581-8	10.2	30
173	Individual prostate-specific antigen (PSA) forms as prostate tumor markers. <i>Clinica Chimica Acta</i> , 1997 , 257, 117-32	6.2	30
172	Systematic review of statistical methods used in molecular marker studies in cancer. <i>Cancer</i> , 2008 , 112, 1862-8	6.4	30

171	Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells in vitro or prostate cancer xenografts in vivo. <i>Prostate</i> , 2003 , 56, 45-53	4.2	30
170	Prostate cancer mortality in areas with high and low prostate cancer incidence. <i>Journal of the National Cancer Institute</i> , 2014 , 106, dju007	9.7	29
169	Chemical characterization of the predominant proteins secreted by mouse seminal vesicles. <i>FEBS Journal</i> , 1997 , 249, 39-44		29
168	Activation of latent protease function of pro-hK2, but not pro-PSA, involves autoprocessing. <i>Prostate</i> , 2001 , 48, 122-6	4.2	29
167	Empirical estimates of the lead time distribution for prostate cancer based on two independent representative cohorts of men not subject to prostate-specific antigen screening. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 1201-7	4	28
166	Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues. <i>Prostate</i> , 2003 , 57, 196-204	4.2	28
165	Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building. <i>Protein Science</i> , 1996 , 5, 836-51	6.3	28
164	Reducing WBC background in cancer cell separation products by negative acoustic contrast particle immuno-acoustophoresis. <i>Analytica Chimica Acta</i> , 2018 , 1000, 256-264	6.6	28
163	Polymorphisms at the Microseminoprotein-beta locus associated with physiologic variation in beta-microseminoprotein and prostate-specific antigen levels. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2035-42	4	27
162	Screening a combinatorial peptide library to develop a human glandular kallikrein 2-activated prodrug as targeted therapy for prostate cancer. <i>Molecular Cancer Therapeutics</i> , 2004 , 3, 1439-50	6.1	27
161	Screening for Prostate Cancer Starting at Age 50-54 Years. A Population-based Cohort Study. <i>European Urology</i> , 2017 , 71, 46-52	10.2	26
160	Eighteen-year follow-up of the Göteborg Randomized Population-based Prostate Cancer Screening Trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. <i>Scandinavian Journal of Urology</i> , 2018 , 52, 27-37	1.6	26
159	Beyond prostate-specific antigen: utilizing novel strategies to screen men for prostate cancer. <i>Current Opinion in Urology</i> , 2016 , 26, 459-65	2.8	26
158	Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer. <i>Current Opinion in Urology</i> , 2009 , 19, 221-6	2.8	26
157	Follow-up of men with elevated prostate-specific antigen and one set of benign biopsies at prostate cancer screening. <i>European Urology</i> , 2003 , 43, 327-32	10.2	26
156	Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival. <i>European Urology</i> , 2018 , 74, 710-719	10.2	25
155	Inhibition of circulating dipeptidyl peptidase 4 activity in patients with metastatic prostate cancer. <i>Molecular and Cellular Proteomics</i> , 2014 , 13, 3082-96	7.6	25
154	Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. <i>Prostate</i> , 2005 , 65, 66-72	4.2	25

153	Stability of serum prostate-specific antigen determination across laboratory, assay, and storage time. <i>Urology</i> , 1995 , 45, 447-53	1.6	25
152	The microheterogeneity of desialylated alpha 1-antichymotrypsin: the occurrence of two amino-terminal isoforms, one lacking a His-Pro dipeptide. <i>BBA - Proteins and Proteomics</i> , 1989 , 997, 90-5		25
151	Effect of androgen deprivation therapy on the expression of prostate cancer biomarkers MSMB and MSMB-binding protein CRISP3. <i>Prostate Cancer and Prostatic Diseases</i> , 2010 , 13, 369-75	6.2	24
150	Time-resolved fluorometry in end-point and real-time PCR quantification of nucleic acids. <i>Luminescence</i> , 2000 , 15, 381-8	2.5	24
149	Feed-forward alpha particle radiotherapy ablates androgen receptor-addicted prostate cancer. <i>Nature Communications</i> , 2018 , 9, 1629	17.4	23
148	Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group. <i>World Journal of Urology</i> , 2014 , 32, 185-91	4	23
147	Porous silicon antibody microarrays for quantitative analysis: measurement of free and total PSA in clinical plasma samples. <i>Clinica Chimica Acta</i> , 2012 , 414, 76-84	6.2	23
146	Integrated acoustic immunoaffinity-capture (IAI) platform for detection of PSA from whole blood samples. <i>Lab on A Chip</i> , 2013 , 13, 1790-6	7.2	23
145	Prostate specific antigen velocity does not aid prostate cancer detection in men with prior negative biopsy. <i>Journal of Urology</i> , 2010 , 184, 907-12	2.5	23
144	Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation. <i>Journal of Urology</i> , 2004 , 171, 1432-5	2.5	23
143	Anti-thrombin is expressed in the benign prostatic epithelium and in prostate cancer and is capable of forming complexes with prostate-specific antigen and human glandular kallikrein 2. <i>American Journal of Pathology</i> , 2002 , 161, 2053-63	5.8	23
142	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. <i>European Urology</i> , 2019 , 75, 399-407	10.2	23
141	Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men. <i>European Urology</i> , 2018 , 73, 941-948	10.2	22
140	Evolution of free, complexed, and total serum prostate-specific antigen and their ratios during 1 year of follow-up of men with febrile urinary tract infection. <i>Urology</i> , 2003 , 62, 278-81	1.6	22
139	Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden. <i>Prostate</i> , 2005 , 65, 216-21	4.2	22
138	The role of molecular forms of prostate-specific antigen (PSA or hK3) and of human glandular kallikrein 2 (hK2) in the diagnosis and monitoring of prostate cancer and in extra-prostatic disease. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2001 , 38, 357-99	9.4	22
137	Improved porous silicon microarray based prostate specific antigen immunoassay by optimized surface density of the capture antibody. <i>Analytica Chimica Acta</i> , 2013 , 796, 108-14	6.6	21
136	Comparison of predictive accuracy for pathologically organ confined clinical stage T1c prostate cancer using human glandular kallikrein 2 and prostate specific antigen combined with clinical stage and Gleason grade. <i>Journal of Urology</i> , 2005 , 173, 752-6	2.5	21

135	Standardization of two immunoassays for human glandular kallikrein 2. <i>Clinical Chemistry</i> , 2003 , 49, 601-10	3.9	21
134	The evolution of the glandular kallikrein locus: identification of orthologs and pseudogenes in the cotton-top tamarin. <i>Gene</i> , 2004 , 343, 347-55	3.8	21
133	Detection of High Grade Prostate Cancer among PLCO Participants Using a Prespecified 4-Kallikrein Marker Panel. <i>Journal of Urology</i> , 2017 , 197, 1041-1047	2.5	20
132	Emerging PSA-based tests to improve screening. <i>Urologic Clinics of North America</i> , 2014 , 41, 267-76	2.9	20
131	Cutpoints in clinical chemistry: time for fundamental reassessment. <i>Clinical Chemistry</i> , 2009 , 55, 15-7	5.5	20
130	Beta-microseminoprotein in serum correlates with the levels in seminal plasma of young, healthy males. <i>Journal of Andrology</i> , 2008 , 29, 330-7		20
129	Androgen receptor CAG repeat length correlates with semen PSA levels in adolescence. <i>Prostate</i> , 2004 , 59, 227-33	4.2	20
128	Microseminoprotein-Beta Expression in Different Stages of Prostate Cancer. <i>PLoS ONE</i> , 2016 , 11, e0150341	3.4	20
127	Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy. <i>Prostate</i> , 2019 , 79, 1079-1089	4.2	19
126	Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms. <i>Journal of Proteomics</i> , 2010 , 73, 1137-47	3.9	19
125	Immunoreactivity of recombinant human glandular kallikrein using monoclonal antibodies raised against prostate-specific antigen. <i>Prostate</i> , 1997 , 31, 84-90	4.2	19
124	Increase in percent free prostate-specific antigen in men with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2009 , 24, 1238-41	4.3	19
123	Testing in serum for human glandular kallikrein 2, and free and total prostate specific antigen in biannual screening for prostate cancer. <i>Journal of Urology</i> , 2003 , 170, 1169-74	2.5	19
122	Time-resolved fluorescence in immunocytochemical detection of prostate-specific antigen in prostatic tissue sections. <i>The Histochemical Journal</i> , 1999 , 31, 45-52		19
121	The proportion of carboxylated to total or intact osteocalcin in serum discriminates warfarin-treated patients from control subjects. <i>Journal of Bone and Mineral Research</i> , 1999 , 14, 555-60	6.3	19
120	Genetic variation in KLK2 and KLK3 is associated with concentrations of hK2 and PSA in serum and seminal plasma in young men. <i>Clinical Chemistry</i> , 2014 , 60, 490-9	5.5	18
119	Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy. <i>International Journal of Cancer</i> , 2009 , 124, 659-63	7.5	18
118	Molecular microheterogeneity of prostate specific antigen in seminal fluid by mass spectrometry. <i>Clinical Biochemistry</i> , 2012 , 45, 331-8	3.5	17

117	Time-resolved fluorescence imaging for specific and quantitative immunodetection of human kallikrein 2 and prostate-specific antigen in prostatic tissue sections. <i>Urology</i> , 2000 , 56, 682-8	1.6	17
116	Simultaneous quantification of human glandular kallikrein 2 and prostate-specific antigen mRNAs in peripheral blood from prostate cancer patients. <i>Journal of Molecular Diagnostics</i> , 2001 , 3, 111-22	5.1	17
115	Chromosome 19 annotations with disease speciation: a first report from the Global Research Consortium. <i>Journal of Proteome Research</i> , 2013 , 12, 135-50	5.6	16
114	Evaluation of prediagnostic prostate-specific antigen dynamics as predictors of death from prostate cancer in patients treated conservatively. <i>International Journal of Cancer</i> , 2011 , 128, 2373-81	7.5	16
113	Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated?. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1112-6	2.2	16
112	A common prostate cancer risk variant 5Qp of microseminoprotein-beta (MSMB) is a strong predictor of circulating beta-microseminoprotein (MSP) levels in multiple populations. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010 , 19, 2639-46	4	16
111	On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer. <i>European Journal of Cancer</i> , 2010 , 46, 3109-19	7.5	16
110	The Four-Kallikrein Panel Is Effective in Identifying Aggressive Prostate Cancer in a Multiethnic Population. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020 , 29, 1381-1388	4	15
109	Androgen Deprivation Therapy Potentiates the Efficacy of Vascular Targeted Photodynamic Therapy of Prostate Cancer Xenografts. <i>Clinical Cancer Research</i> , 2018 , 24, 2408-2416	12.9	15
108	Cancer-associated changes in the expression of TMPRSS2-ERG, PCA3, and SPINK1 in histologically benign tissue from cancerous vs noncancerous prostatectomy specimens. <i>Urology</i> , 2014 , 83, 511.e1-7	1.6	15
107	Predicting prostate cancer many years before diagnosis: how and why?. <i>World Journal of Urology</i> , 2012 , 30, 131-5	4	15
106	A highly conserved protein secreted by the prostate cancer cell line PC-3 is expressed in benign and malignant prostate tissue. <i>Biological Chemistry</i> , 2007 , 388, 289-95	4.5	15
105	Internalization of secreted antigen-targeted antibodies by the neonatal Fc receptor for precision imaging of the androgen receptor axis. <i>Science Translational Medicine</i> , 2016 , 8, 367ra167	17.5	15
104	Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC). <i>Journal of Clinical Oncology</i> , 2017 , 35, 1297-1303	2.2	14
103	Preclinical imaging of kallikrein-related peptidase 2 (hK2) in prostate cancer with a (111)In-radiolabelled monoclonal antibody, 11B6. <i>EJNMMI Research</i> , 2014 , 4, 51	3.6	14
102	A comparison of the free fraction of serum prostate specific antigen in men with benign and cancerous prostates: the best case scenario. <i>Journal of Urology</i> , 1996 , 156, 350-4	2.5	14
101	Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis. <i>Cancer</i> , 2016 , 122, 3386-3393	6.4	14
100	Properties of the 4-Kallikrein Panel Outside the Diagnostic Gray Zone: Meta-Analysis of Patients with Positive Digital Rectal Examination or Prostate Specific Antigen 10 ng/ml and Above. <i>Journal of Urology</i> , 2017 , 197, 607-613	2.5	13

99	Three genes expressing Kunitz domains in the epididymis are related to genes of WFDC-type protease inhibitors and semen coagulum proteins in spite of lacking similarity between their protein products. <i>BMC Biochemistry</i> , 2011 , 12, 55	4.8	13
98	Risk of dying from prostate cancer in men randomized to screening: differences between attendees and nonattendees. <i>Cancer</i> , 2009 , 115, 5672-9	6.4	13
97	Expression and immunolocalisation of neutral endopeptidase in prostate cancer. <i>European Urology</i> , 2003 , 44, 415-22	10.2	13
96	Simultaneous Quantification of Prostate-specific Antigen and Human Glandular Kallikrein 2 mRNA in Blood Samples from Patients with Prostate Cancer and Benign Disease. <i>Clinical Chemistry</i> , 2002 , 48, 1265-1271	5.5	13
95	Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. <i>JAMA Network Open</i> , 2020 , 3, e1919284	10.4	12
94	Molecular insights into substrate specificity of prostate specific antigen through structural modeling. <i>Proteins: Structure, Function and Bioinformatics</i> , 2009 , 77, 984-93	4.2	12
93	Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio. <i>European Urology</i> , 2004 , 45, 160-5	10.2	12
92	Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer. <i>Current Urology Reports</i> , 2004 , 5, 231-40	2.9	12
91	Quantitative PSA RT-PCR for preoperative staging of prostate cancer. <i>Prostate</i> , 2003 , 56, 263-9	4.2	12
90	Anthropometric Measures at Multiple Times Throughout Life and Prostate Cancer Diagnosis, Metastasis, and Death. <i>European Urology</i> , 2015 , 68, 1076-82	10.2	11
89	Baseline prostate-specific antigen measurements and subsequent prostate cancer risk in the Danish Diet, Cancer and Health cohort. <i>European Journal of Cancer</i> , 2013 , 49, 3041-8	7.5	11
88	Serum markers in prostate cancer detection. <i>Current Opinion in Urology</i> , 2015 , 25, 59-64	2.8	11
87	A Highly Sensitive Porous Silicon (P-Si)-Based Human Kallikrein 2 (hK2) Immunoassay Platform toward Accurate Diagnosis of Prostate Cancer. <i>Sensors</i> , 2015 , 15, 11972-87	3.8	10
86	Genome-wide association study identifies loci at ATF7IP and KLK2 associated with percentage of circulating free PSA. <i>Neoplasia</i> , 2013 , 15, 95-101	6.4	10
85	NADiA ProVue prostate-specific antigen slope is an independent prognostic marker for identifying men at reduced risk of clinical recurrence of prostate cancer after radical prostatectomy. <i>Urology</i> , 2012 , 80, 1319-25	1.6	10
84	Targeting free prostate-specific antigen for in vivo imaging of prostate cancer using a monoclonal antibody specific for unique epitopes accessible on free prostate-specific antigen alone. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012 , 27, 243-51	3.9	10
83	Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(1) or Lys(2) from fPSA without internal cleavages at Lys(1) or Lys(2) <i>Journal of Immunological Methods</i> , 2011 , 369, 74-80	2.5	10
82	Novel homogenous time-resolved fluorometric RT-PCR assays for quantification of PSA and hK2 mRNAs in blood. <i>Clinical Biochemistry</i> , 2007 , 40, 111-8	3.5	10

81	Measurement of Circulating Forms of Prostate-specific Antigen in Whole Blood Immediately after Venipuncture: Implications for Point-of-Care Testing. <i>Clinical Chemistry</i> , 2001 , 47, 703-711	5.5	10
80	Dual-label detection of amplified products in quantitative RT-PCR assay using lanthanide-labeled probes. <i>BioTechniques</i> , 2001 , 30, 832-6, 838, 840 passim	2.5	10
79	A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study. <i>Lancet Oncology</i> , 2021 , 22, 1618-1631	21.7	10
78	Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. <i>Journal of Urology</i> , 2002 , 168, 1917-22	2.5	10
77	A urinary extracellular vesicle microRNA biomarker discovery pipeline; from automated extracellular vesicle enrichment by acoustic trapping to microRNA sequencing. <i>PLoS ONE</i> , 2019 , 14, e0217507	3.7	9
76	Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. <i>British Journal of Cancer</i> , 2018 , 118, 266-276	8.7	9
75	Porous silicon microarray for simultaneous fluorometric immunoassay of the biomarkers prostate-specific antigen and human glandular kallikrein 2. <i>Mikrochimica Acta</i> , 2016 , 183, 3321-3327	5.8	9
74	Association of transcript levels of 10 established or candidate-biomarker gene targets with cancerous versus non-cancerous prostate tissue from radical prostatectomy specimens. <i>Clinical Biochemistry</i> , 2013 , 46, 670-4	3.5	9
73	Identification of plasma protein profiles associated with risk groups of prostate cancer patients. <i>Proteomics - Clinical Applications</i> , 2014 , 8, 951-62	3.1	9
72	MALDI-target integrated platform for affinity-captured protein digestion. <i>Analytica Chimica Acta</i> , 2014 , 807, 1-8	6.6	9
71	Test sensitivity in the European prostate cancer screening trial: results from Finland, Sweden, and the Netherlands. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009 , 18, 2000-5	4	9
70	A frequent allele codes for a truncated variant of semenogelin I, the major protein component of human semen coagulum. <i>Molecular Human Reproduction</i> , 2003 , 9, 345-50	4.4	9
69	Prostate Cancer Risk-Associated Single-Nucleotide Polymorphism Affects Prostate-Specific Antigen Glycosylation and Its Function. <i>Clinical Chemistry</i> , 2019 , 65, e1-e9	5.5	9
68	Value of Intact Prostate Specific Antigen and Human Kallikrein 2 in the 4 Kallikrein Predictive Model: An Individual Patient Data Meta-Analysis. <i>Journal of Urology</i> , 2018 , 199, 1470-1474	2.5	8
67	Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. <i>European Urology</i> , 2018 , 73, 961-967	10.2	8
66	Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?. <i>BJU International</i> , 2013 , 112, 602-9	5.6	8
65	Intra-individual short-term variability of prostate-specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer. <i>BJU International</i> , 2011 , 107, 1769-74	5.6	8
64	Measurements of proteases or protease system components in blood to enhance prediction of disease risk or outcome in possible cancer. <i>Journal of Clinical Oncology</i> , 2007 , 25, 347-8	2.2	8

63	Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3). <i>Scandinavian Journal of Urology and Nephrology</i> , 2003 , 37, 466-70		8
62	Prespecified 4-Kallikrein Marker Model at Age 50 or 60 for Early Detection of Lethal Prostate Cancer in a Large Population Based Cohort of Asymptomatic Men Followed for 20 Years. <i>Journal of Urology</i> , 2020 , 204, 281-288	2.5	8
61	Genetic signature of prostate cancer mouse models resistant to optimized hK2 targeted nanoparticle therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020 , 117, 15172-15181	11.5	7
60	Prediction of tumor heterogeneity in localized prostate cancer. <i>Urologic Clinics of North America</i> , 2002 , 29, 213-22	2.9	7
59	Time-resolved fluorescence imaging (TRFI) for direct immunofluorescence of PSA and alpha-1-antichymotrypsin in prostatic tissue sections. <i>Prostate Cancer and Prostatic Diseases</i> , 1999 , 2, 140-147	6.2	7
58	A Four-kallikrein Panel and Microseminoprotein in Predicting High-grade Prostate Cancer on Biopsy: An Independent Replication from the Finnish Section of the European Randomized Study of Screening for Prostate Cancer. <i>European Urology Focus</i> , 2019 , 5, 561-567	5.1	7
57	Radiolabeled antibodies in prostate cancer: a case study showing the effect of host immunity on antibody bio-distribution. <i>Nuclear Medicine and Biology</i> , 2015 , 42, 375-80	2.1	6
56	Prostate cancer risk SNP rs10993994 is a trans-eQTL for SNHG11 mediated through MSMB. <i>Human Molecular Genetics</i> , 2020 , 29, 1581-1591	5.6	6
55	We need a better marker for prostate cancer. How about renaming PSA?. <i>Urology</i> , 2012 , 79, 254-5	1.6	6
54	Evaluation of a new immunoassay for cystatin C, based on a double monoclonal principle, in men with normal and impaired renal function. <i>Nephrology Dialysis Transplantation</i> , 2012 , 27, 682-7	4.3	6
53	Successful separation between benign prostatic hyperplasia and prostate cancer by measurement of free and complexed PSA. <i>Cancer Treatment and Research</i> , 1996 , 88, 93-101	3.5	6
52	Acoustophoresis in Tumor Cell Enrichment 2016 , 227-248		5
51	Rapid elimination kinetics of free PSA or human kallikrein-related peptidase 2 after initiation of gonadotropin-releasing hormone-antagonist treatment of prostate cancer: potential for rapid monitoring of treatment responses. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012 , 50, 1993-8	5.9	5
50	Cloning and characterization of the alpha 1-antichymotrypsin produced by human prostate tissue. <i>Prostate</i> , 1998 , 34, 155-61	4.2	5
49	Prostate cancer risk assessment in men with an initial P.S.A. below 3 ng/mL: results from the Göteborg randomized population-based prostate cancer screening trial. <i>Scandinavian Journal of Urology</i> , 2018 , 52, 256-262	1.6	5
48	Detection of androgen receptor mutations in circulating tumor cells: highlights of the long road to clinical qualification. <i>Clinical Chemistry</i> , 2010 , 56, 1375-7	5.5	4
47	Testing new PSA subforms to enhance the accuracy of predicting cancer risk and disease outcome in prostate cancer. <i>Clinical Chemistry</i> , 2008 , 54, 1248-9	5.5	4
46	Analysis of AR-FL and AR-V1 in Whole Blood of Patients with Castration Resistant Prostate Cancer as a Tool for Predicting Response to Abiraterone Acetate. <i>Journal of Urology</i> , 2020 , 204, 71-78	2.5	4

45	Perspective on Prostate Cancer Screening. <i>Clinical Chemistry</i> , 2019 , 65, 24-27	5.5	4
44	A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. <i>British Journal of Cancer</i> , 2020 , 123, 604-609	8.7	3
43	The continuing role of prostate-specific antigen as a marker for localized prostate cancer: Do not throw the baby out with the bath water <i>BJU International</i> , 2009 , 104, 1553-4	5.6	3
42	Can PSA velocity predict risk of death in men with prostate cancer?. <i>Nature Reviews Urology</i> , 2007 , 4, 410-1		3
41	Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues. <i>Prostate</i> , 2001 , 47, 14-20	4.2	3
40	Tumor volume is a valid surrogate endpoint for defining clinically significant prostate cancers. <i>European Urology</i> , 2001 , 39 Suppl 4, 33-4	10.2	3
39	DETECTION OF PROSTATE CANCER: PSA 2011 , 283-334		3
38	HK2 MEASUREMENTS IN A RANDOMLY SELECTED, POPULATION BASED SCREENING FOR PROSTATE CANCER. <i>Journal of Urology</i> , 1999 , 320	2.5	3
37	High-Throughput and Automated Acoustic Trapping of Extracellular Vesicles to Identify microRNAs With Diagnostic Potential for Prostate Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 631021	5.3	3
36	Five genetic variants associated with prostate cancer. <i>New England Journal of Medicine</i> , 2008 , 358, 2740; author reply 2741	59.2	3
35	Re: Tobias Nordström, Andrew Vickers, Melissa Assel, Hans Lilja, Henrik Gröbberg, Martin Eklund. Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer. <i>Eur Urol</i> 2015;68:139-46. <i>European Urology</i> , 2018 , 74, e35-e36	10.2	2
34	Suitability of quality control materials for prostate-specific antigen (PSA) measurement: inter-method variability of common tumor marker control materials. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013 , 51, 873-80	5.9	2
33	Copy number variants in the kallikrein gene cluster. <i>PLoS ONE</i> , 2013 , 8, e69097	3.7	2
32	Bioinformatic strategies for unambiguous identification of prostate specific antigen in clinical samples. <i>Journal of Proteomics</i> , 2011 , 75, 202-10	3.9	2
31	Altered expression of epithelial-to-mesenchymal transition proteins in extraprostatic prostate cancer. <i>Oncotarget</i> , 2016 , 7, 1107-19	3.3	2
30	Genome-wide association study identifies novel single nucleotide polymorphisms having age-specific effect on prostate-specific antigen levels. <i>Prostate</i> , 2020 , 80, 1405-1412	4.2	2
29	Special Issue on Men's Health. <i>Clinical Chemistry</i> , 2019 , 65, 1-3	5.5	2
28	Kallikrein markers performance in pretreatment blood to predict early prostate cancer recurrence and metastasis after radical prostatectomy among very high-risk men. <i>Prostate</i> , 2020 , 80, 51-56	4.2	2

27	PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates. <i>Clinical Cancer Research</i> , 2021 , 27, 2050-2060	12.9	2
26	Prostate cancer polygenic risk score and prediction of lethal prostate cancer.. <i>Npj Precision Oncology</i> , 2022 , 6, 25	9.8	2
25	Two-Step Acoustophoresis Separation of Live Tumor Cells from Whole Blood.. <i>Analytical Chemistry</i> , 2021 , 93, 17076-17085	7.8	2
24	1986 AN EMPIRICAL EVALUATION OF THE NATIONAL CANCER CENTER NETWORK GUIDELINES ON PROSTATE SPECIFIC ANTIGEN VELOCITY IN PROSTATE CANCER DETECTION. <i>Journal of Urology</i> , 2010 , 183,	2.5	1
23	Editorial comment. Association between glomerular filtration rate, free, total, and percent free prostate-specific antigen. <i>Urology</i> , 2010 , 76, 1046-7; author reply 1047	1.6	1
22	Screening for prostate cancer. <i>Annals of Internal Medicine</i> , 2012 , 156, 539; author reply 540	8	1
21	Characterization of the BRCA1-like immunoreactivity of human seminal plasma. <i>Urology</i> , 1999 , 54, 753-62.6		1
20	Biologic Function of Prostate-Specific Antigen: Enzyme Action and Reactions with Extracellular Protease Inhibitors. <i>European Urology</i> , 1995 , 27, 2-3	10.2	1
19	Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: pilot study.. <i>BJU International</i> , 2021 ,	5.6	1
18	Long-term prediction of prostate cancer diagnosis and death using PSA and obesity related anthropometrics at early middle age: data from the malmö preventive project. <i>Oncotarget</i> , 2018 , 9, 5778-5785	3.3	1
17	DISCRIMINATION OF MEN WITH PROSTATE CANCER FROM THOSE WITH BENIGN DISEASE BY MEASUREMENTS OF HUMAN GLANDULAR KALLIKREIN 2 (HK2) IN SERUM. <i>Journal of Urology</i> , 2000 , 311	2.5	1
16	Identification of a serum biomarker signature associated with metastatic prostate cancer. <i>Proteomics - Clinical Applications</i> , 2021 , 15, e2000025	3.1	1
15	Cloning and characterization of the α -antichymotrypsin produced by human prostate tissue 1998 , 34, 155		1
14	Seminal progastricsin. <i>Advances in Experimental Medicine and Biology</i> , 1995 , 362, 101-5	3.6	1
13	The significance of serpins in the regulation of proteases in the male genital tract. <i>Advances in Experimental Medicine and Biology</i> , 1997 , 425, 163-76	3.6	1
12	Results from 22 years of Follow-Up in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial.. <i>Journal of Urology</i> , 2022 , 101097JU0000000000002696	2.5	1
11	Prospective validation of microseminoprotein- α added to the 4Kscore in predicting high-grade prostate cancer in an international multicentre cohort. <i>BJU International</i> , 2021 , 128, 218-224	5.6	0
10	Clinical Consultation Guide: How to Optimize the Use of Prostate-specific Antigen in the Current Era. <i>European Urology Focus</i> , 2015 , 1, 149-151	5.1	

- 9 Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer. *Current Prostate Reports*, **2005**, 3, 11-20
- 8 Reply by Authors. *Journal of Urology*, **2020**, 204, 77-78 2.5
- 7 Discrimination of Benign From Malignant Prostatic Disease by Selective Measurements of Single Chain, Intact Free Prostate Specific Antigen. *Journal of Urology*, **2002**, 1917-1922 2.5
- 6 A pre-specified statistical model based on four kallikrein markers in blood to predict advanced pathology on radical prostatectomy.. *Journal of Clinical Oncology*, **2018**, 36, 5073-5073 2.2
- 5 Reply by Authors. *Journal of Urology*, **2020**, 204, 287-288 2.5
- 4 Quantitative Time-Resolved Fluorescence Imaging of Androgen Receptor and Prostate-Specific Antigen in Prostate Tissue Sections. *Journal of Histochemistry and Cytochemistry*, **2016**, 64, 311-22 3.4
- 3 Reply to Re: The Memorial Sloan Kettering Cancer Center Recommendations for Prostate Cancer Screening. *Urology*, **2016**, 95, 224 1.6
- 2 Reply to Kathryn L. Penney, Massimo Loda, and Meir J. Stampfer@ Letter to the Editor re: Melissa Assel, Anders Dahlin, David Ulmert, et al. Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening. *Eur Urol* 2018;73:961-7. *European Urology*, 2019, 75, e56 10.2
- 1 PSA: role in screening and monitoring patients with prostate cancer **2022**, 131-172